BCL2L1 and colorectal carcinoma: Given that MCL-1 and BCL-xL are co-expressed in late-stage CRC, this chemoresistance can be countered by coadministration of A-1331852 (BCL-xL inhibitor) and A-1210477 (MCL-1 inhibitor) [162].